



DRUG REGULATORY AUTHORITY OF PAKISTAN

Division of Quality Assurance and Laboratory Testing

RAPID ALERT

DRAP ALERT No: N° I/S/10-25-88

CRACKDOWN AGAINST UNLICENSED / UNAUTHORIZED MANUFACTURERS

Date: 14th October, 2025

Target Audience:

- Regulatory Field Force of DRAP and Provincial Drug Control departments.
- Healthcare Professionals
- Consumers

Problem Statement:

Directorate of Drugs Control Punjab (DDCP) informed the Drug Regulatory Authority of Pakistan (DRAP) that the following purported drug product has been declared '**spurious/falsified**' upon analysis and reportedly manufactured by entity not licensed or authorized by DRAP. The relevant laboratory findings and product details are as under:

S#	Product Name	Batch No.	Manufacturer	Remarks
1.	COXETO 120mL. (SUSPECTED TO CONTAIN VITAMIN E, VITAMIN D AND COPPER SULPHATE)	005/APN,	ALI's Pakistan Plot # 10, Street # 01, Al-Ghani Estate, Dullu Khurd Industrial Area, Ferozpur Road, Lahore.	'Falsified' Sample contains suspected ingredients i.e. Vitamin E and does not contain Vitamin D & Copper Sulphate.
2.	Payodine 60ml Each 100ml contains: Povidone-Iodine 10 gm equivalent to 1.0 gm available Iodine (1% w/v)	2709	S.A.R LAB Plot # 186, Korangi No. 04, Industrial Area Karachi	Sample declared as ' Spurious '

Risk Statement:

Purported drug product has been confirmed as falsified/spurious, as manufactured by entity neither licensed nor authorized by the Drug Regulatory Authority of Pakistan (DRAP). This product being illegally manufactured and marketed without regulatory oversight, rendering their quality, safety, and efficacy highly doubtful. Laboratory testing has revealed the absence of active pharmaceutical ingredient, indicating a complete lack of therapeutic value. The circulation and use of such unregulated product pose a serious risk to public health, including treatment



DRAP, Islamabad

+ 92 051 9255969

gsms@dra.gov.pk



DRUG REGULATORY AUTHORITY OF PAKISTAN

Division of Quality Assurance and Laboratory Testing

failure, disease progression, and potential life-threatening consequences. The public is strongly advised to avoid the use of these unregistered drug products and report any suspicious or unauthorized medicines to DRAP through its official reporting channels.

Action Initiated: -

The Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.

Advice for Healthcare Professionals: -

DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using [Adverse Event Reporting Form](#) or online through this [link](#). Further information on reporting problems to DRAP is available on this [link](#).

Advice for Consumers:

Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.



Drug Regulatory Authority of Pakistan

محفوظ، موثر اور معیاری اشیائے علاج

